US OptionsDetailed Quotes
SGMO241220C1000
- 1.15
- +0.05+4.55%
15min DelayClose Nov 27 16:00 ET
1.15High1.15Low
1.15Open1.10Pre Close9 Volume561 Open Interest1.00Strike Price1.04KTurnover0.00%IV-6.52%PremiumDec 20, 2024Expiry Date1.30Intrinsic Value100Multiplier21DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.00Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Sangamo Therapeutics Stock Discussion
Sign in to post a comment
$Sangamo Therapeutics (SGMO.US)$ watch this today
1
$Rumble (RUM.US)$ $Red Cat Holdings (RCAT.US)$ $Microvision (MVIS.US)$ $Bit Digital (BTBT.US)$ $Wix.com (WIX.US)$ $Sangamo Therapeutics (SGMO.US)$ $Above Food Ingredients (ABVE.US)$ $Exicure (XCUR.US)$ $Hoth Therapeutics (HOTH.US)$ $Kingsoft Cloud (KC.US)$ $Digital Brands Group (DBGI.US)$ $Tevogen Bio Holdings (TVGN.US)$ $Nauticus Robotics (KITT.US)$ $Tonix Pharmaceuticals (TNXP.US)$
📊⚡️📊
📊⚡️📊
4
5
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Fresh2 (FRES.US)$ $Opus Genetics (IRD.US)$ $Sangamo Therapeutics (SGMO.US)$ $Kindly MD (KDLY.US)$ $Edesa Biotech (EDSA.US)$ $Sadot (SDOT.US)$ $Lazydays (GORV.US)$ $Zeo Energy (ZEO.US)$ $Hall Of Fame Resort & Entertainment (HOFV.US)$ $Nauticus Robotics (KITT.US)$ $KORE Group (KORE.US)$ $Digital Brands Group (DBGI.US)$ $Hoth Therapeutics (HOTH.US)$ $Tonix Pharmaceuticals (TNXP.US)$
📊⚡️📊
📊⚡️📊
4
$Sangamo Therapeutics (SGMO.US)$ Sangamo Therapeutics Gets FDA Clearance Of IND Application For ST-503 For Treatment Of Idiopathic Small Fiber Neuropathy
Benzinga· 3 mins ago
Benzinga· 3 mins ago
4
3
$Sangamo Therapeutics (SGMO.US)$
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Sangamo plans to initiate enrollment of patients in thePhase 1/2 study for ST-503 in mid-2025
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for i...
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Sangamo plans to initiate enrollment of patients in thePhase 1/2 study for ST-503 in mid-2025
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for i...
1
$Sangamo Therapeutics (SGMO.US)$
S-3: Registration statement for specified transactions by certain issuers
“This registration statement contains two prospectuses:
•
a base prospectus, which covers the offering, issuance and sale by the registrant of up to a maximum aggregate offering price of $500,000,000 of the registrant’s common stock, preferred stock, debt securities and/or warrants from time to time in one or more offerings; and
•
a sales agreement prospectus, which cov...
S-3: Registration statement for specified transactions by certain issuers
“This registration statement contains two prospectuses:
•
a base prospectus, which covers the offering, issuance and sale by the registrant of up to a maximum aggregate offering price of $500,000,000 of the registrant’s common stock, preferred stock, debt securities and/or warrants from time to time in one or more offerings; and
•
a sales agreement prospectus, which cov...
3
No comment yet
Exactly : I watch this since ww2